BioMarin Pharmaceutical Inc. (BMRN) stock has gained 1.56% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.
BioMarin Pharmaceutical Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BMRN!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With BMRN Stock Today?
BioMarin Pharmaceutical Inc. (BMRN) stock is trading at $76.25 as of 10:42 AM on Thursday, Oct 28, a gain of $4.53, or 6.32% from the previous closing price of $71.72. The stock has traded between $72.61 and $77.29 so far today. Volume today is elevated. So far 1,759,692 shares have traded compared to average volume of 1,187,050 shares.
More About BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Click Here to get the full Stock Report for BioMarin Pharmaceutical Inc. stock.